{
  "abstract": "Cardio-oncology has emerged as a vital subspecialty addressing the cardiovascular effects of cancer and its therapies. As the prevalence of cancer survivorship grows, so too does the need for integrated care models to prevent and manage treatment-related cardiovascular complications. The 2022 European Society of Cardiology (ESC) Guidelines on Cardio-Oncology provide a comprehensive framework for managing these risks through collaborative, multidisciplinary care.1 Yet, one key healthcare professional group remains largely underrepresented: hospital pharmacists.",
  "authors": [
    {
      "affiliations": [
        "Health Research Department, Hospital Clinica Biblica, San José, Costa Rica",
        "Faculty of Pharmacy, Universidad de Iberoamerica, San José, Costa Rica"
      ],
      "name": "Esteban Zavaleta-Monestel"
    },
    {
      "affiliations": [
        "Health Research Department, Hospital Clinica Biblica, San José, Costa Rica"
      ],
      "name": "Sebastian Arguedas-Chacon"
    },
    {
      "affiliations": [
        "Pharmacy Department, Hospital Clinica Biblica, San José, Costa Rica"
      ],
      "name": "Kevin Cruz-Mora"
    },
    {
      "affiliations": [
        "Pharmacy Department, Hospital Clinica Biblica, San José, Costa Rica"
      ],
      "name": "Jeaustin Mora-Jimenez"
    }
  ],
  "title": "Hospital pharmacists in cardio-oncology: bridging a critical gap in multidisciplinary cancer care",
  "uid": "d1faad4a-2bab-50a6-b29b-202ea9e414ec"
}